Table 1 Baseline characteristics
Prior sunitinib only | Prior pazopanib only | Prior anti–PD-1/PD-L1 | ||||
|---|---|---|---|---|---|---|
Cabozantinib N = 135 | Everolimus N = 132 | Cabozantinib N = 88 | Everolimus N = 83 | Cabozantinib N = 18 | Everolimus N = 14 | |
Median age, years (range) | 62.0 (37–79) | 62.0 (31–81) | 63.0 (38–86) | 61.0 (36–84) | 63.5 (47–81) | 61.0 (37–84) |
Sex, n (%) | ||||||
Male | 106 (79) | 95 (72) | 68 (77) | 64 (77) | 13 (72) | 11 (79) |
Female | 29 (21) | 36 (27) | 20 (23) | 19 (23) | 5 (28) | 3 (21) |
Missing | 0 | 1 (1) | 0 | 0 | 0 | 0 |
Enrollment region, n (%) | ||||||
Europe | 72 (53) | 66 (50) | 34 (39) | 34 (41) | 6 (33) | 6 (43) |
North America | 45 (33) | 43 (33) | 35 (40) | 32 (39) | 11 (61) | 7 (50) |
Asia Pacific | 18 (13) | 22 (17) | 13 (15) | 13 (16) | 1 (6) | 1 (7) |
Latin America | 0 | 1 (1) | 6 (7) | 4 (5) | 0 | 0 |
ECOG performance statusa, n (%) | ||||||
0 | 95 (70) | 87 (66) | 66 (75) | 49 (59) | 12 (67) | 9 (64) |
1 | 40 (30) | 45 (34) | 22 (25) | 34 (41) | 6 (33) | 5 (36) |
MSKCC risk group, n (%) | ||||||
Favourable | 55 (41) | 60 (45) | 40 (45) | 35 (42) | 5 (28) | 6 (43) |
Intermediate | 63 (47) | 58 (44) | 39 (44) | 37 (45) | 9 (50) | 7 (50) |
Poor | 17 (13) | 14 (11) | 9 (10) | 11 (13) | 4 (22) | 1 (7) |
Sum of target lesion diameters, mm (range) | 60.1 (0–291) | 60.6 (0–231) | 66.7 (0–240) | 60.7 (0–217) | 92.0 (0–194) | 83.0 (16–190) |
Metastatic sites per IRC, n (%) | ||||||
Lung | 80 (59) | 88 (67) | 62 (70) | 54 (65) | 10 (56) | 11 (79) |
Liver | 43 (32) | 55 (42) | 22 (25) | 16 (19) | 6 (33) | 4 (29) |
Bone | 27 (20) | 23 (17) | 20 (23) | 18 (22) | 5 (28) | 4 (29) |
Lymph node | 83 (61) | 78 (59) | 48 (55) | 47 (57) | 11 (61) | 10 (71) |
Number of prior VEGFR TKIs, n (%) | ||||||
1 | 135 (100) | 132 (100) | 88 (100) | 83 (100) | 7 (39) | 8 (57) |
≥2 | 0 | 0 | 0 | 0 | 11 (61) | 6 (43) |
Prior systemic therapy, n (%) | ||||||
Sunitinib | 135 (100) | 132 (100) | 0 | 0 | 12 (67) | 9 (64) |
Pazopanib | 0 | 0 | 88 (100) | 83 (100) | 11 (61) | 6 (43) |
Axitinib | 0 | 0 | 0 | 0 | 5 (28) | 3 (21) |
Sorafenib | 0 | 0 | 0 | 0 | 1 (6) | 2 (14) |
Bevacizumab | 0 | 3 (2) | 1 (1) | 3 (4) | 1 (6) | 1 (7) |
Interleukins | 7 (5) | 7 (5) | 4 (5) | 7 (8) | 2 (11) | 0 |
Interferons | 4 (3) | 7 (5) | 6 (7) | 5 (6) | 1 (6) | 0 |
Anti–PD- 1/PD-L1 | 5 (4) | 5 (4) | 2 (2) | 3 (4) | 18 (100) | 14 (100) |
Radiotherapy, n (%) | 39 (29) | 41 (31) | 35 (40) | 26 (31) | 6 (33) | 5 (36) |
Nephrectomy, n (%) | 116 (86) | 112 (85) | 76 (86) | 65 (78) | 16 (89) | 11 (79) |
